List view / Grid view
Immigration law experts from Fragomen LLP discuss currently challenges in the UK’s visa system and propose recommendations for attracting science and technology talent that support the country’s competitiveness.
Biotechnology Innovation Organization (BIO) and the International Generic and Biosimilar medicines Association (IGBA) highlight the need for industry cooperation to support the potential impact of tarrifs.
The drug is the first in a new class of oral antibiotics for uncomplicated urinary tract infections in nearly three decades.
26 March 2025 | By Thermo Fisher Scientific Pharma Services
This webinar explores oral drug product development and how to address critical challenges such as complex formulations and regulatory hurdles.
The new license agreement will support development of a potential additional treatment option for patients at risk of atherosclerosis.
The research highlights a potential approach to address cross-contamination challenges during cell-processing operations.
The anti-amyloid drug study highlights the importance of longer-term follow-up to determine benefits and risks of dementia treatments.
EPR Issue 1 includes articles on manufacturing, drug delivery, process analytical technology (PAT), RNA therapeutics and more.
The new data shows potential of the psilocybin treatment to provide durable, longer-term antidepressant effects in patients with treatment-resistant depression (TRD).
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
The throughput achieved by the researchers exceeded that of other reported methods by orders of magnitude, supporting the advancement of precision nanomaterials.
The European marketing authorisation offers a new treatment option for patients with transfusion-dependent anaemia in lower-risk myelodysplastic syndromes (LR-MDS), who are unresponsive to erythropoiesis-stimulating agents.
14 March 2025 | By
A collaboration with Pfizer to create a tool to ensuring seamless method transfer between labs.
Approximately 1,000 eligible NHS patients could benefit from the new endometriosis treatment annually.
Investment in the new manufacturing plant strengthens Merck (MSD)’s vaccine production capacity in the US.
